论文部分内容阅读
目的 :了解T、B免疫双标记型急性淋巴细胞白血病 (ALL)的临床特点 ,以判断预后与指导治疗。方法 :对 4 89例形态学上诊断为ALL的病例 ,取其外周血或骨髓 ,分离出单个核细胞 ,应用APAAP法进一步作免疫表型分析 ,对其中同时表达T、B淋巴细胞表面抗原的免疫双标记型病例的临床特点、化疗疗效及预后进行观察。结果 :4 7例患者同时表达T、B淋巴细胞表面特异性抗原。在临床方面 ,与T淋巴细胞系ALL相比 ,肝、脾、淋巴结肿大或纵隔肿块发生率、白细胞数量均较低 (P <0 .0 5 ) ,但化疗完全缓解率及存活期差异无显著性意义(P >0 .0 5 ) ;与B淋巴细胞系ALL相比 ,肝、脾、淋巴结肿大及纵隔肿块发生率均较高 (P <0 .0 5 ) ,而白细胞数量差异无显著性意义 (P >0 .0 5 ) ,但化疗完全缓解率高、存活期较长 (P <0 .0 5 )。结论 :免疫双标记型ALL在临床上可能属预后较好的造血系统肿瘤
Objective: To understand the clinical features of T and B immunodominant acute lymphoblastic leukemia (ALL) in order to judge prognosis and guide treatment. Methods: A total of 4 89 cases with morphologically diagnosed ALL were collected. Peripheral blood or bone marrow was obtained from the peripheral blood or bone marrow. Mononuclear cells were isolated. APAAP method was used to further analyze the immunophenotype. The expression of T, B lymphocyte surface antigen Immunological double-labeled cases of clinical features, efficacy and prognosis of chemotherapy were observed. Results: 47 cases of patients expressed T, B lymphocyte surface antigen. Clinically, the incidence of hepatic, splenic, lymphadenopathy or mediastinal mass and leukocyte count were lower than those of T lymphocyte ALL (P <0.05), but the rates of complete remission and survival were no difference (P0.05). Compared with B lymphocyte line ALL, the incidence of liver, spleen, lymph nodes and mediastinal mass were higher (P0.05), while the number of white blood cells was no significant difference Significant significance (P> 0.05), but the chemotherapy complete remission rate, longer survival (P <0. 05). Conclusion: Immuno-double-labeled ALL may be clinically a hematopoietic tumor with a good prognosis